Positive Outcome Reached at 16 Weeks for Avexa Limited's ATC Phase III Trial

Published: Jun 04, 2009

MELBOURNE, Australia--(BUSINESS WIRE)--Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa’s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy.

Back to news